124 related articles for article (PubMed ID: 38224761)
1. Biodistribution and pharmacokinetics of [
García-Varela L; Codesido J; Perez-Pedrosa A; Muñoz-González M; Ramos-Docampo E; Rey-Bretal D; García-Otero X; Gómez-Lado N; Turrero A; Beiroa D; Rodríguez-Perez AI; Vidal A; Fernández-Ferreiro A; Pubul V; Aguiar P
Int J Pharm; 2024 Mar; 652():123795. PubMed ID: 38224761
[TBL] [Abstract][Full Text] [Related]
2. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies and absorbed dose estimation of [
Zolghadri S; Mohammadpour-Ghazi F; Yousefnia H
Appl Radiat Isot; 2024 Aug; 210():111379. PubMed ID: 38815448
[TBL] [Abstract][Full Text] [Related]
4. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
5.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
6. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
7. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Characterization of
Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126
[No Abstract] [Full Text] [Related]
9. PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats.
Luaces-Rodríguez A; Del Amo EM; Mondelo-García C; Gómez-Lado N; Gonzalez F; Ruibal Á; González-Barcia M; Zarra-Ferro I; Otero-Espinar FJ; Fernández-Ferreiro A; Aguiar P
Eur J Pharm Biopharm; 2020 Sep; 154():330-337. PubMed ID: 32659326
[TBL] [Abstract][Full Text] [Related]
10. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
11. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
[TBL] [Abstract][Full Text] [Related]
12. Application of
Stergiou N; Wuensche TE; Schreurs M; Mes I; Verlaan M; Kooijman EJM; Windhorst AD; Helboe L; Vergo S; Christensen S; Asuni AA; Jensen A; Van Dongen GAMS; Bang-Andersen B; Vugts DJ; Beaino W
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1306-1317. PubMed ID: 36635462
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
[TBL] [Abstract][Full Text] [Related]
14. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
16. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
17. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
18. Development of [
Ghai A; Zheleznyak A; Mixdorf M; O'Neal J; Ritchey J; Rettig M; DiPersio J; Shokeen M; Achilefu S
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1302-1311. PubMed ID: 33179150
[TBL] [Abstract][Full Text] [Related]
19. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
20. A generic
Li N; Yu Z; Pham TT; Blower PJ; Yan R
Int J Nanomedicine; 2017; 12():3281-3294. PubMed ID: 28458546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
